Abstract: We describe a method of selectively testing a liquid sample for the presence of a specific living biological entity, the method comprising: preparing a plurality of culture vessels each for selective detection of the presence of a different living biological entity, wherein preparing a said culture vessel comprises: providing a culture vessel comprising a sealable chamber for receiving and culturing a liquid sample such that presence of said biological entity is detectable by detecting a change in pressure in a head space of said chamber; providing a selective growth medium in said culture vessel, wherein said selective growth medium is in a dry form and selectively facilitates growth of a specific living biological entity, and providing the culture vessel with an identifier to identity said specific biological entity; providing a test system comprising a device to receive said culture vessel and to detect said change in pressure in said head space of said chamber, the device further comprising a temperature

Abstract: A method of testing for pathogens can include applying a pathogen indicating substance to an object, the pathogen indicating substance having one characteristic when not in contact with a pathogen and another characteristic when in contact with a pathogen, and generating a signal indicative of the level of pathogen contamination on the object by quantifying the presence of the pathogen indicating substance with the pathogen indicating characteristic on the object. An apparatus for testing for pathogens can include a dispenser for dispensing a pathogen indicating substance, the pathogen indicating substance having one characteristic which is altered to another characteristic on contact with a pathogen, a main sensor for detecting a level of pathogen contamination by quantifying the pathogen indicating substance having the pathogen indicating characteristic, and a control unit for generating a signal indicative of the level of pathogen contamination detected by the sensor.

Abstract: A method and system of preparing a sample for microbial testing by providing a sample in a sample bag, a dry sterile growth medium in a bag, and a source of pure (Type II) water heated to a temperature of about 25-50° C., homogenizing the sample, reconstituting the dry medium with the heated Type II water, mixing the medium and sample to a homogenous consistency and incubating the sample for a period of time sufficient to allow the growth of microbes. A tankless water heater or a heat exchanger can be used to heat the water to a desired temperature. The Type II water can be heated either before or after it is made. A blender can be used for the sample homogenization as well as the final mixing before incubation and may be a paddle or stationary blender. Microbes are detected by various methods well known in the art.

Abstract: This invention relates to the field of medium and nitrogen fixation technique. More specifically, the present invention relates to a method of identifying whether Azotobacter secrets ammonia using nitrogen-free solid incubation media. Each liter of nitrogen-free incubation media comprises: K2HPO4 0.5-2 g, MgSO4.7H2O 0.1-0.5 g, CaCl2.2H2O 0.05-0.15 g, glucose 7-13 g, FeSO4.7H2O 0.005-0.02 g, NaMoO4.2H2O, 0.005-0.01 g, agar 10-20 g, and distilled water to balance. The present invention provides a method to identify whether Azotobacter secrets ammonia using nitrogen-free solid incubation media, which is simple and easy to carry out, and can accurately identify whether Azotobacter secreting nitrogenous compounds to extracellular and the ability of secretion, which play an important role in the development of bio-fertilizer industry.

Abstract: A method of analysing a sample including a microorganism of interest. The method includes exposing the sample to an antimicrobial; after exposing the sample to the antimicrobial, applying an absorption-based and/or scattering-based spectroscopic technique to the sample to obtain spectrum data whose spectral profile has been influenced by exposing the sample to the antimicrobial, wherein applying the absorption-based and/or scattering-based spectroscopic technique to the sample includes irradiating the sample with UV-Vis radiation; obtaining information regarding the susceptibility/resistance of the microorganism of interest to the antimicrobial from the spectrum data. The absorption-based and/or scattering-based spectroscopic technique may be applied to the sample no more than 60 minutes after the initial exposure of the sample to the antimicrobial.

Abstract: The present invention relates to a device for measuring the antimicrobial activity of a gas and a method for measuring the antimicrobial activity of a gas. The present invention can be used as a standardized device for measuring the antimicrobial activity of a gas or as a standardized method for measuring the antimicrobial activity of a gas as the present invention is capable of constantly maintaining the concentration of a gas and identifying the growth and development of microorganisms objectively through a color change of a microorganism culture medium containing a pH indicator.

Abstract: The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.

Abstract: Analytical apparatuses are disclosed for detecting at least one analyte in a sample, where in an analyte measurement at least an electrical or optical property changeable by presence of the analyte at least one test chemical of a test element is recorded, and where the analytical apparatus also can perform at least one quality measurement on the at least one test chemical such as an intrinsic luminescence, which is recorded and from the intrinsic luminescence a conclusion is drawn on a quality of the test chemical and thus the test element. Methods also are disclosed for detecting at least one analyte in a sample that include a quality measurement of the at least one test chemical of the test strip.

Abstract: Method includes providing a droplet actuator having a droplet-operations gap and a plurality of electrodes positioned along the droplet-operations gap. The method also includes positioning an input droplet in the droplet-operations gap. The input droplet has a starting concentration of a substance-of-interest. The method also includes conducting droplet operations within the droplet-operations gap using the electrodes to generate discrete dilution droplets that are formed from the input droplet. The dilution droplets and a remainder of the input droplet form a droplet set. At least two of the dilution droplets in the droplet set having different concentrations of the substance-of-interest. The method also includes combining a select number of the droplets from the droplet set to form an output droplet having a modified concentration that is substantially equal to a designated target concentration.

Abstract: The disclosure provides for methods, compositions, and kits for normalizing nucleic acid libraries, for example sequencing libraries.

Abstract: Methods for multiplex amplification of a plurality of targets of distinct sequence from a complex mixture are disclosed. In one aspect targets are circularized using a single circularization probe that is complementary to two regions in the target that flank a region to be amplified. The targets may hybridize to the circularization probe so that 5? or 3? flaps are generated and methods for removing flaps and circularizing the resulting product are disclosed. In another aspect targets are hybridized to dU probes so that 5? and 3? flaps are generated. The flaps are cleaved using 5? or 3? flap endonucleases or 3? to 5? exonucleases. The target sequences are then ligated to common primers, the dU probes digested and the ligated targets amplified.

Abstract: The invention is directed to methods of removing amplicons of non target and/or target nucleic acid sequences having one or more modified (e.g., methylated) nucleotides from a sample wherein the sample comprises the non target nucleic acid and a target nucleic acid sequence to be amplified.

Abstract: The present invention relates to a carbapenemase and methods using said carbapenemase such as detection methods, screening methods, predictive methods and therapeutic uses.

Abstract: A method of diagnosing severe sepsis prior to definitive clinical diagnosis. A pattern of gene expression that correlates strongly with a future diagnosis of severe sepsis and organ failure was identified in patients who had their blood drawn at first clinical presentation. The methods comprise identifying a pattern of two or more polynucleotides, whereby the altered expression of these polynucleotides correlates with prospective and actual sepsis. Also methods of identifying agents for treating sepsis based on the characteristics of this gene expression pattern are provided.

Abstract: The present invention provides improved systems, methods and software for determining a pathway activation strength in old subjects relative to young subjects of the same species, the method including collecting young subject transcriptome data and old subject transcriptome data for one species to evaluate pathway activation strength (PAS) and down-regulation strength for a plurality of biological pathways, mapping the plurality of biological pathways for the activation strength and down-regulation strength from old subject samples relative to young subject samples to form a pathway cloud map and providing a gero-protective rating for each of a plurality of drugs in accordance with a drug rating for minimizing signaling pathway cloud disturbance (SPCD) in the pathway cloud map of the one species to provide a ranking of the gero-protective drugs.

Abstract: Sequence specific DNA amplification and analysis techniques are provided. In some aspects, methods of the embodiments comprise amplifying sequence from two regions of a target sequence in the presence of a blocking oligonucleotide (e.g., such as a phosphorothioate-containing oligonucleotide) that hybridizes to the target sequence between the two regions. In some specific embodiments, a method is provided for detecting bacteria (such as detecting gram-positive or gram-negative bacteria) in a biological sample using polymerase chain reaction (PCR).

Abstract: This invention relates to the detection and diagnosis of tuberculosis. More specifically, the invention relates to new biomarkers and combinations thereof that enable the accurate detection and diagnosis of tuberculosis.

Abstract: The invention is directed to compositions and methods for rapidly detecting, amplifying, and quantitating one or more pathogen-specific nucleic acids in a biological sample, and in particular, samples obtained from patients with sepsis. The invention also provides diagnostic kits containing specific amplification primers, and labeled detection probes that specifically bind to the amplification products obtained therefrom. The invention is also directed to detecting the quantity or ratio of genomic sequences and mRNA sequences of an individual suspected of being infected with an infectious agent over time to assess the progress of the infection over time. Also disclosed are compositions and methods for the isolation and characterization of nucleic acids that are specific to one or more pathogens, such as, for example, Influenza virus, Mycobacterium tuberculosis, Plasmodium, and/or HIV from a wide variety of samples including those of biological, environmental, clinical and/or veterinary origin.

Abstract: Retrieval of one or more samples from a pediatric subject for genetic analysis of the subject's nucleic acid is often invasive and inconvenient. Methods for analyzing nucleic acid include non-invasive and/or convenient methods of sample retrieval such as the retrieval of one or more samples for genetic analysis from a patient that may have an infection in conjunction with testing for the infection. In one aspect, the infection is strep throat. Methods for analyzing nucleic acid may also include the retrieval of a sample from a placenta that has been delivered during birth of a child. In one aspect, the sample is cord blood and in another aspect the sample is chorion tissue. Methods for analyzing nucleic acid include conducting a genetic analysis on the retrieved sample by exposing a nucleic acid to a plurality of MIPs and subsequently sequencing and aligning and assembling the reads generated therefrom.

Abstract: Translocation control for sensing by a nanopore, as well as methods and products related to the same, are provided. Such methods optimize duplex stability to provide high fill rate (of the hybridization sites) but do not prevent rapid dissociation required for high read rates, as well as controlling the translocation of a target molecule for sensing by a nanopore by use of a selective pulsed voltage. Products related to the same include a reporter construct comprising two or more phosphoramidites.

Abstract: Provided herein are methods and devices for single object detection. The methods and devices can be used to identify a plurality epigenetic markers on a genetic material, or a chromatin, encompassing fragments thereof. The invention provides for the characterization of the genetic material flowing through a channel in a continuous body of fluid based on detection of one or more properties of the genetic material. The methods and systems provided herein allow genome-wide, high-throughput epigenetic analysis and overcome a variety of limitations common to bulk analysis techniques.

Abstract: Methods and apparatus providing for the isolation of an unknown mutation from a sample comprising wild type nucleic acids and mutated nucleic acids through the application of time-varying driving fields and periodically varying mobility-altering fields to the sample within in an affinity matrix.

Abstract: A fluorous-modified composition, a fluorous nucleoside, nucleotide, or oligonucleotide microarray, a compositional detection process, a process of forming a fluorous nucleoside, nucleotide, or oligonucleotide microarray, and fluorous nucleoside, nucleotide, or oligonucleotide microarray processes are disclosed. The fluorous-modified composition includes a linker, a nucleoside, nucleotide, or oligonucleotide connected to the linker, and a fluorous domain connected to the linker. The fluorous-modified composition includes at least one terminal perfluoroalkyl group in the fluorous domain, a solid-phase attachment group connected to the linker, or a combination thereof. The compositional detection process includes using the fluorous microarray for compositional detection.

Abstract: The present invention relates to the detection of a target nucleic acid sequence by a PTOCE (PTO Cleavage and Extension) assay. The present invention detects a target nucleic acid sequence in which the PTO (Probing and Tagging Oligonucleotide) hybridized with the target nucleic acid sequence is cleaved to release a fragment and the fragment is hybridized with the CTO (Capturing and Templating Oligonucleotide) to form an extended duplex, followed by detecting the presence of the extended duplex. The extended duplex provides signals (generation, increase, extinguishment or decrease of signals) from labels indicating the presence of the extended duplex and has adjustable Tm value, which are well adoptable for detection of the presence of the target nucleic acid sequence.

Abstract: A system and method for capturing and analyzing a set of cells, comprising: an array including a set of parallel pores, each pore including a chamber including a chamber inlet and a chamber outlet, and configured to hold a single cell, and a pore channel fluidly connected to the chamber outlet; an inlet channel fluidly connected to each chamber inlet of the set of parallel pores; an outlet channel fluidly connected to each pore channel of the set of parallel pores; a set of electrophoresis channels fluidly coupled to the outlet channel, configured to receive a sieving matrix for electrophoretic separation; and a set of electrodes including a first electrode and a second electrode, wherein the set of electrodes is configured to provide an electric field that facilitates electrophoretic analysis of the set of cells.

Abstract: This disclosure relates to novel detergents for use in various procedures including, for example, nucleic acid amplification reactions such as polymerase chain reaction (PCR). Methods for preparing the modified detergents are also described.

Abstract: Sensitive, unbiased methods for genome-wide detection of potential off-target nuclease cleavage sites in DNA, e.g., in cell type-specific genomic DNA samples.

Abstract: It has been established that one or more large double stranded DNA fragments (each 2,000 to 40,000 base pairs in size) can be captured and isolated from genomic DNA fragments using sequence specific PNA hybridization probes. Compositions and methods for enrichment of a multiplicity of long DNA sequences selected from the genome of any eukaryote are provided. Capture is performed using multiple PNA molecules with gamma-modified chiral backbones, comprising a mixture of neutral and positive chemical groups. Two or more PNA probes with covalently bound haptens, preferably biotin, target each DNA domain of interest for capture, isolation, and subsequent sequencing analysis of the multiplicity of enriched targets, including DNA methylation sequencing. The methods include enhancement of probe-DNA binding specificity through single strand binding proteins (SSB).

Abstract: The present invention relates to a method for the determination of a nucleic acid sequence by physical manipulation. The method is based on the precise determination of the localization of the replicating fork on the template by measuring the physical distance between one end of the molecule and the fork. This allows the determination of the physical location of the site where a pause or a blockage of the replication occurs, and deducing therefrom information on the sequence of the nucleic acid.

Abstract: A method comprises magnetically holding a bead carrying biological material (e.g., nucleic acid, which may be in the form of DNA fragments or amplified DNA) in a specific location of a substrate, and applying an electric field local to the bead to isolate the biological material or products or byproducts of reactions of the biological material. For example, the bead is isolated from other beads having associated biological material. The electric field in various embodiments concentrates reagents for an amplification or sequencing reaction, and/or concentrates and isolates detectable reaction by-products. For example, by isolating nucleic acids around individual beads, the electric field can allow for clonal amplification, as an alternative to emulsion PCR. In other embodiments, the electric field isolates a nanosensor proximate to the bead, to facilitate detection of at least one of local pH change, local conductivity change, local charge concentration change and local heat.

Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

Abstract: This invention is to describe nucleotide analogs used in a method for the determination of a nucleic acid sequence. The method involves an enzyme, an enzyme complex or plural number of enzymes with more than one enzymatic activity and a set of nucleotide analogs, to achieve high signal readout accuracy in nucleic acid sequencing by making each signal to have a long signaling time span which allows a higher signal clarity.

Abstract: The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological and/or mitochondrial dysfunction or disorder. In general, the individuals are treated and/or classified based on the presence of a loss-of-function mutation in nuclear DNA encoding one or more proteins selected from the group consisting of ALDH1L1, ALDH1L2, FOLR1, FPGS, GCSH, GLDC, MTHFD1, MTHFD1L, MTHFD2, MTHFD2L, MTHFS, MTRR, SHMT1, SHMT2 and SLC25A32. Treatment involves the administration of a therapeutically effective amount of folinic acid, glycine or a pharmaceutically acceptable salt thereof.

Abstract: Pharmacogenetic analysis revealed an effect of risk alleles in ARMS2 and CFH genes on the response of subjects to anti-C5 antibodies in the treatment of the progression of geographic atrophy.

Abstract: The invention provides methods and compositions for the treatment of a subject having a psychiatric disease or dis order based upon the subject's genotype and/or the number of risk alleles carried by the subject, which risk alleles have been found by the present inventors to predispose a subject to antipsychotic medication induced weight gain (AIWG). The methods of the inven tion also provide for different treatments, or different treatment regimens, for the subject depending on the subject's risk of AIWG. Related compositions, in the form of kits, systems, and computer-readable media are also provided.

Abstract: Technology provided herein relates in part to methods, processes and apparatuses for non-invasive assessment of genetic variations. In particular the invention relates to methods and kits for detecting aneuploidy of a fetal chromosome by determining the amounts of differentially methylated regions in each of chromosomes 13, 18 and 21 in circulating cell-free nucleic acid from a human pregnant female.

Abstract: Methods and kits for selectively enriching non-random polynucleotide sequences are provided. Methods and kits for generating libraries of sequences are provided. Methods of using selectively enriched non-random polynucleotide sequences for detection of fetal aneuploidy are provided.

Abstract: The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into a linear discrimination analysis where the linear discrimination analysis normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the linear discrimination analysis or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers.

Abstract: Systems and methods for mitigating prostate cancer development are provided. Peripheral blood cells may be evaluated for the presence or quantity of gamma-H2AX foci, and/or for gene alterations encoding a protein with impaired or lack of function, for example, because the encoded protein is truncated, and correlating with prostate cancer development. Such nucleic acids may encode proteins from or peripheral to the DNA damage repair pathway and/or androgen receptor signaling pathway, or that are otherwise correlated with prostate cancer development. Such genes include one or more of AKR1C1, PALB2, APTX, BLM, BRCA1, CTBP1, DDB2, FANCA, FANCL, MBD5, MSH3, NEIL3, RAD51D, RAD54L2, SP1, TP53BP1, UBE2D3, UBE2V2, NRIP1, EFCAB6, CRISP3, PAPSS2, ATP6V0A2, ALG13, MGAT2, B3GAT3, DOLK, FLT3, ASXL1, KDR, or NOTCH2.

Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.

Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.

Abstract: The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.

Abstract: Methods, kits, devices, and computer systems are provided for obtaining an NSCLC marker level representation for an individual with non small cell lung carcinoma (NSCLC); and/or for providing a prognosis for an individual with NSCLC. The methods can include measuring expression levels, in a biological sample, of 2 or more NSCLC markers selected from: MAD2L1, GINS1, SLC2A1, KRT6A, FCGRT, TNIK, BCAM, KDM6A, and FAIM3; calculating an NSCLC marker level representation based on the measured expression levels; comparing the NSCLC marker level representation of the individual to a reference marker level representation; providing a prognosis based on the comparison; and/or generating a report that includes at least one of: (i) an NSCLC marker level representation, (ii) an NSCLC marker level representation and a reference NSCLC marker level representation, (iii) a prognosis, and (iv) guidance to a clinician as to a treatment recommendation based on the prognosis.

Abstract: Disclosed is the provision of a method for assisting the detection of pancreatic cancer, the method assisting the detection of pancreatic cancer with high accuracy. In the method for assisting the detection of pancreatic cancer, the amounts of (1) miR-122-5p and (2) at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p, all of which are contained in a test sample separated from a living body, are used as indicators. A larger amount of miR-122-5p and a smaller amount of at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p than those in a healthy individual indicates that the living body is more likely to have developed pancreatic cancer.

Abstract: The invention provides an assay useful in predicting risk of 5-fluorouracil (FU) toxicity in a subject. The subject may be screened for the presence of at least one TYMS polymorphism and/or at least one DPYD polymorphism. Suitable TYMS and DPYD polymorphisms are provided. The presence of one or more of the polymorphisms indicates an increased risk of developing FU toxicity; a negative result may indicate a decreased risk of developing FU toxicity.

Abstract: Provided is an approach for differentially determining the histological type of a lung cancer lesion objectively and rapidly with high accuracy. A method for differentially assessing a lesion in a lung cancer patient as squamous cell carcinoma or adenocarcinoma, comprising a step of measuring an expression level of an expression product of at least one DNA comprising a transcription start site in a biological sample collected from the lesion, wherein the DNA comprises a base at an arbitrary position in the transcription start site and at least one or more bases located immediately downstream thereof in any of nucleotide sequences represented by SEQ ID NOs: 1 to 213, and the transcription start site is a region wherein both ends thereof are defined by the first base and the 101st base counted from the 3? end in any of the nucleotide sequences represented by SEQ ID NOs: 1 to 213.

Abstract: Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.

Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding s

Abstract: The present invention provides, inter alia, kits for selecting a chemotherapy regimen for a subject. The kits comprise one or more components for detecting the expression of at least one gene from the group of SLC12A7, GZMB, TAF6L, NFIB, METRN, ROPN1B, TTK, CCND1, PTTG1, H2AFZ, WDR45L, DEK, MCM2, USP1, CDT1, TMEM97, RER1, MCM6, LZTFL1, C11orf17, CCL5, XCL1, XCL2, MELK, CTSL2, TPX2, AURKA, CDKN2C, BRP44, PNP, SMC4, NR4A2, C3orf37, MTPAP, CDC25B, ABCF1, MTAP, SNAPC3, RANBP9, COIL, FAM86B1, ITGA6, S100P, RANBP1, PRSS16, SMARCA2, STK24, TSPYL5, SRI, LRP12, CENPF, TUBD1, KIAA1324, DBF4, CCNA2, DLGAP5, FHL1, SIRT3, GTSE1, PCNA, CCNE2, CHD3, CAP1, GPM6B, GUSBP3, GNAI3, LMO4, PSRC1, USP1, STK38, BAT2L1, PMP22, NME5, CENPA, BANK1, and derivatives thereof. Methods for selecting a chemotherapy regimen for a subject are also provided.

Abstract: Disclosed is a method for supporting a diagnosis of a risk of colorectal cancer recurrence, including the steps of: performing a first measurement to measure the levels of expression of a plurality of genes selected from a first gene group present in a region from 18q21 to 18q23 on the long arm of chromosome 18 in a biological sample collected from a patient with colorectal cancer, a second measurement to measure the levels of expression of a plurality of genes selected from a second gene group present in a region from 20q11 to 20q13 on the long arm of chromosome 20, and a third measurement to measure the levels of expression of a plurality of genes selected from a third gene group including ANGPTL2, AXL, C1R, C1S, CALHM2, CTSK, DCN, EMP3, GREM1, ITGAV, KLHL5, MMP2, RAB34, SELM, SRGAP2P1, and VIM; and determining the risk of colorectal cancer recurrence of the patient based on the levels of expression measured in the measurement step.